Form 4: Arvinas CEO Sells Shares for Tax Obligations

Arvinas President and CEO Randy Teel sold 4,786 shares of common stock to cover tax withholding obligations related to restricted stock unit vesting.

Summary

• Randy Teel, President and CEO of Arvinas, Inc. (ARVN), reported the sale of common stock.
• A total of 4,786 shares were sold across two separate transactions on February 23, 2026.
• The shares were sold at a price of $12.16 per share.
• The sales were non-discretionary and automatically executed by the Issuer to cover tax withholding obligations.
• These tax obligations arose from the vesting and settlement of restricted stock units (RSUs) granted on February 22, 2023, and February 23, 2024.
• Following these transactions, Randy Teel beneficially owns 149,696 shares of Arvinas common stock.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive event. While it involves a sale of shares, it's a non-discretionary transaction tied to RSU vesting, indicating executive compensation is being realized, which is a normal part of an executive's compensation package.

Positives

• The reported sales are a result of restricted stock units (RSUs) vesting, indicating the executive is receiving compensation and retaining a significant stake in the company.
• The sales were non-discretionary, solely for tax withholding, rather than a voluntary divestment by the executive.

Negatives

• The transactions resulted in a reduction of Randy Teel's direct beneficial ownership by 4,786 shares.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that routine insider transactions, such as sales to cover tax obligations upon RSU vesting, are common across all industries, particularly in biotechnology where executive compensation often includes significant equity components. These types of filings typically do not reflect a change in the company's strategic direction or operational performance.

Comparison to Industry Standards

• This type of non-discretionary sale for tax purposes is a standard practice for executives receiving equity compensation across publicly traded companies, aligning with common compensation structures in the biotech sector.

Stakeholder Impact

• Shareholders: Minimal direct impact as this is a routine, non-discretionary transaction for tax purposes and does not signal a change in management's confidence or company fundamentals.
• Employees: No direct impact mentioned.

Key Dates

Recommendation

This Form 4 filing details a routine, non-discretionary sale of shares by the CEO to cover tax obligations arising from RSU vesting. It does not provide new material information regarding the company's operational performance, financial health, or strategic outlook. Therefore, a seasoned investor would likely maintain their current position, as this transaction does not warrant a change in investment thesis.

Keywords

Arvinas, ARVN, Randy Teel, Insider Transaction, Form 4, Restricted Stock Units, RSU Vesting, Tax Withholding, Common Stock Sale